AUGMENT Trial – Patient Worthy

$Syndax Pharmaceutical’s Revumenib Meets its Primary Endpoint to Treat Relaxed/Refractory Acute AML$

Syndax Pharmaceutical’s Revumenib Meets its Primary Endpoint to Treat Relaxed/Refractory Acute AML

Post author:Rose Duesterwald
Post published:October 29, 2025
Post category:Acute Myeloid Leukemia

According to a press release from Syndax Pharmaceuticals, the developer of Revumenib, the drug met its primary endpoint resulting in complete remission (CR) or CR with partial recovery. Relapsed or…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More